Clinical trials: Follicular Lymphoma
Restless Legs Syndrome
Long-term Study Of Ropinirole In Restless Legs Syndrome
This is an initial placebo-controlled study followed by open treatment evaluating the effectiveness and tolerability of ropinirole long-term in patients with moderate to severe Restless Legs Syndrome.
- Trial name
- NCT00329602
- Testing
- Ropinirole
- Where
- 39 sites in Australia, Czechia and 9 more
- Volunteers
- 404 people
- Sponsor
- GlaxoSmithKline
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL.
- Conditions
- Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma
- Trial name
- NCT02631044
- Testing
- JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule
- Where
- 14 sites in United States
- Volunteers
- 387 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Follicular Lymphoma
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
A Phase 2, single arm, open label clinical study to evaluate the efficacy, safety, tolerability and pharmacokinetics of YY-20394 as monotherapy in patients with relapsed/refractory follicular non-Hodgkin's lymphoma who have…
- Trial name
- NCT04379167
- Testing
- YY-20394
- Volunteers
- 140 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Moderate/Severe Asthma
NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART
The primary objective of this non-interventional study is to evaluate efficacy of Symbicort® SMART treatment in adult patients with moderate to severe asthma using ACQ scores during 6 months period
- Trial name
- NCT00785733
- Where
- 44 sites in Romania
- Volunteers
- 1,182 people
- Sponsor
- AstraZeneca
Lymphoma, B-Cell, Lymphoma, Follicular
An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice
This observational study aims to assess the therapeutic responsiveness of MabThera SC in patients with malignant lymphomas under everyday clinical practice conditions.
- Trial name
- NCT02240316
- Where
- Germany
- Volunteers
- 688 people
- Sponsor
- Hoffmann-La Roche
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- Trial name
- NCT05878184
- Testing
- SC291
- Where
- 10 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Sana Biotechnology
Grade I or II Essential Hypertension
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
The objective of this study is to compare the efficacy and safety of combined administration of TAK-536CCB (Fix-dose combination of Azilsartan and Amlodipine) and Hydrochlorothiazide (HCTZ) with those of TAK-536CCB in patients…
- Trial name
- NCT02072330
- Testing
- TAK-536CCB, TAK-536CCB + Hydrochlorothiazide, Hydrochlorothiazide
- Where
- 13 sites in Japan
- Volunteers
- 353 people
- Sponsor
- Takeda
Traumatic Brain Injury
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure…
- Trial name
- NCT05951777
- Testing
- Autologous HB-adMSCs, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Hope Biosciences LLC
Follicular Lymphoma, Lymphoma, Follicular
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
This study will treat follicular lymphoma patients who have not received previous treatment with R-CVP. Half of the patients will receive Zevalin after R-CVP and the other half will receive only R-CVP.
- Trial name
- NCT00384111
- Testing
- Zevalin Therapeutic Regimen, R-CVP
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Lymphoma, Non-Hodgkin
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL.
- Trial name
- MAGNIFY (NCT01996865)
- Testing
- Lenalidomide, Rituximab
- Where
- 126 sites in United States, Germany and 1 more
- Volunteers
- 503 people
- Sponsor
- Celgene
Lymphoma
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
The purpose of this study is to assess the clinical benefit of Nivolumab, as measured by independent radiologic review committee (IRRC)-assessed objective response rate (ORR) in subjects with FL lymphoma who have failed therapy…
- Trial name
- NCT02038946
- Testing
- Nivolumab
- Where
- 45 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Bristol-Myers Squibb
Follicular Lymphoma
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
This is a phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in subjects diagnosed with follicular lymphoma (FL) that is relapsed or refractory to either chemotherapy or radioimmunotherapy…
- Trial name
- NCT04707079
- Testing
- Duvelisib
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals
Primary Objective: Conduct pilot study to assess effects of brief negotiation interview (BNI) Chatbot among individuals involved in the Connecticut criminal justice system with opioid use disorder (OUD).
- Conditions
- Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
- Trial name
- BNICHAT (NCT04982627)
- Testing
- BNI Chatbot, OUD Education & Treatment Resources
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Center for Progressive Recovery, LLC
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Yosemite (NCT01732913)
- Testing
- Rituximab, Idelalisib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 295 people
- Sponsor
- Gilead Sciences
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00005959
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 27 sites in United States
- Sponsor
- Amgen
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma
- Trial name
- NCT01109069
- Testing
- PCI-32765
- Where
- 16 sites in United States
- Volunteers
- 199 people
- Sponsor
- Pharmacyclics LLC.
Follicular Lymphoma, Small Lymphocytic Lymphoma
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
The primary objective of this study is to evaluate the overall response rate (ORR) and complete response (CR) rate to treatment with idelalisib in combination with rituximab in previously untreated adults with follicular lymphoma…
- Trial name
- NCT02258529
- Testing
- Idelalisib, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
Asthma
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.
- Trial name
- NCT02105012
- Testing
- BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg
- Where
- 41 sites in United States
- Volunteers
- 147 people
- Sponsor
- Pearl Therapeutics, Inc.
Acne Vulgaris
TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris
The purpose of this study is to determine the safety and effectiveness of TSN 2898 topical gel in the treatment of moderate to severe acne.
- Trial name
- NCT02796066
- Testing
- Vehicle, TSN2898
- Where
- 6 sites in United States, Dominican Republic and 1 more
- Volunteers
- healthy volunteers welcome
- Sponsor
- Thesan Pharmaceuticals, Inc.